Non-Hodgkin Lymphoma

NON-HODGKIN LYMPHOMA NEWS TIPS & FEATURES

Gazyva® Delays Cancer Progression as Initial Therapy in Advanced Follicular Lymphoma

January 5th, 2017

Gazyva® Delays Cancer Progression as Initial Therapy in Advanced Follicular Lymphoma

Among patients with advanced follicular lymphoma who have not received prior therapy, treatment with Gazyva® (obinutuzumab) plus chemotherapy delays cancer progression compared to the standard […]


Progress Reported in New Treatments for People with Lymphoma

December 29th, 2016

Progress Reported in New Treatments for People with Lymphoma

Research and pharmaceutical executives unveil encouraging clinical trial data at the annual meeting of the American Society of Hematology. Twenty-two years ago, Dr. Gary Gordon, […]


Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma

December 15th, 2016

Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma

Treatment including the targeted agent Gazyva (obinutuzumab) delays cancer progression for a longer period of time than treatment with Rituxan (rituximab) among patients with follicular […]


Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

December 1st, 2016

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring […]


The First CAR-T Therapy Heading to the FDA

September 29th, 2016

The First CAR-T Therapy Heading to the FDA

Kite Pharma reported that its CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with aggressive non Hodgkin lymphoma. […]


Pass it On: It's Leukemia and Lymphoma National Awareness Month

September 1st, 2016

Pass it On: It’s Leukemia and Lymphoma National Awareness Month

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will […]


Opdivo® Highly Effective for Some Patients with Lymphomas

August 16th, 2016

Opdivo® Highly Effective for Some Patients with Lymphomas

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell […]


CancerConnect Launches Online Community for Patients Diagnosed with Histiocytosis

June 24th, 2016

CancerConnect Launches Online Community for Patients Diagnosed with Histiocytosis

Sun Valley ID & Austin TX– OMNI Health Media (OMNI) announces the launch of a new online community on CancerConnect for adults affected by histiocytosis. […]


CAR Therapy Effective in Advanced Lymphoma

June 20th, 2016

CAR Therapy Effective in Advanced Lymphoma

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear […]


Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in Follicular Lymphoma

June 8th, 2016

Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in Follicular Lymphoma

A study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin’s lymphoma (iNHL) suggests that  Gazyva® (obinutuzumab) plus chemotherapy […]


More News →